Associated Papers
Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations.
Le LT et al.
The Application of Clinical Genetics, 2025
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F et al.
The Oncologist, 2024
Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
Zheng S et al.
Molecular Biomedicine, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Neurodevelopmental disorders and cancer networks share pathways, but differ in mechanisms, signaling strength, and outcome.
Yavuz BR et al.
Npj Genomic Medicine, 2023
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S et al.
Current Oncology (toronto, Ont.), 2022
Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.
Kim Y et al.
Cancer Cell International, 2021
The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.
Fu X et al.
Frontiers in Oncology, 2021
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Huang RSP et al.
The Oncologist, 2020
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Li K et al.
Breast Cancer Research and Treatment, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.
Guo Y et al.
Frontiers in Oncology, 2020
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P et al.
Scientific Reports, 2019
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Saida K et al.
Oncotarget, 2018
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X et al.
International Journal of Clinical Oncology, 2016
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G et al.
Journal of Translational Medicine, 2016
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F et al.
Medical Oncology (northwood, London, England), 2016
Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Additional Options for an Orphan Cancer.
Roa I et al.
The Journal of Molecular Diagnostics : Jmd, 2016
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G et al.
Oncotarget, 2015
Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
Bumrungthai S et al.
Journal of Translational Medicine, 2015
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Corso G et al.
European Journal of Human Genetics : Ejhg, 2013
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Schneck H et al.
Molecular Oncology, 2013
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
Giudice FS et al.
Journal of Carcinogenesis & Mutagenesis, 2013
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H et al.
International Journal of Clinical Oncology, 2013
Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
Ang D et al.
The Journal of Molecular Diagnostics : Jmd, 2013
Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y et al.
Plos One, 2013
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.
Palomba G et al.
Journal of Translational Medicine, 2012
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
Mao C et al.
Plos One, 2012
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
Molinari F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Oncogenic mutations in gastric cancer with microsatellite instability.
Corso G et al.
European Journal of Cancer (oxford, England : 1990), 2011
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J et al.
Breast Cancer Research and Treatment, 2010
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Platt FM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
Nosho K et al.
Neoplasia (new York, N.y.), 2008
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z et al.
Cancer Research, 2007
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Kozaki K et al.
Cancer Science, 2006